Indivior PLC (OTCMKTS:INVVY – Get Free Report) shares traded down 1.8% during trading on Friday. The stock traded as low as $21.64 and last traded at $21.8455. 8,100 shares were traded during mid-day trading, an increase of 112% from the average session volume of 3,825 shares. The stock had previously closed at $22.25.
Indivior Stock Performance
The firm has a market capitalization of $3.01 billion, a P/E ratio of 20.81 and a beta of 0.35. The stock has a 50-day moving average of $21.85 and a 200 day moving average of $21.85.
About Indivior
Indivior is a pharmaceutical company focused on treatments for substance use disorders, particularly opioid use disorder, as well as select mental health conditions. Its products include SUBLOCADE, an extended-release buprenorphine injection, and SUBOXONE, a buprenorphine and naloxone treatment for opioid use disorder. The company also markets PERSERIS, an extended-release risperidone injection for schizophrenia. Indivior was established as an independent company in 2014 through a demerger from Reckitt Benckiser.
Further Reading
- Five stocks we like better than Indivior
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.
